The adverse roles of TGF-β at different stages of MI could also increase its complexity for clinic application, so careful assessments must be undertaken to determine how TGF-β could be adopted in clinical treatment to improve ventricular remodeling. This evidence concerns the gene TGFB1 and myocardial infarction.